Jinwu Financial News | China Securities Co., Ltd. released a Research Report indicating that Ascentage Pharma (06855)'s Nelotanserin and APG-2575 presented multiple clinical data at the ASH conference. Among them, Nelotanserin demonstrated good results in second-line CP-CML patients, with 74% of patients achieving CCyR after treatment, and the product still showed a 37.5% CCyR in patients resistant to Asciminib, showing excellent efficacy. At the same time, APG-2575 showed good preliminary efficacy data in both MM and MDS. The firm believes that the two drugs from the company demonstrate outstanding efficacy in multiple hematological malignancies, and with the gradual advancement of clinical trials, positive clinical data for the products can be expected in the future.

The firm pointed out that the company has built multiple product pipelines in areas such as hematologic cancers and solid tumors, and with the driving force of potent BIC potential products, future revenue is expected to maintain high growth. The firm predicts that Ascentage Pharma will achieve revenues of 0.981, 0.568, and 0.877 billion yuan from 2024 to 2026, with year-on-year growth rates of 341.93%, -42.10%, and 54.45%, and maintains a 'Buy' rating.